英國研發(fā)貼片新冠疫苗

Oxfordshire-based company Emergex will soon start clinical trials of a second-generation vaccine against COVID-19, an easy-to-administer skin patch that uses T-cells to kill infected cells and could offer longer-lasting immunity than current vaccines. The vaccine will eventually be administered as a skin patch the size of a thumbnail bristling with micro-needles that release the shot within seconds.

英國牛津郡的Emergex公司將針對第二代新冠疫苗開展臨床試驗(yàn)。Emergex公司的這款疫苗利用T細(xì)胞殺死被感染的細(xì)胞，最終將以"拇指大小的皮膚貼片"形式接種，易于注射，且可以提供比現(xiàn)有疫苗更持久的免疫力。當(dāng)貼片接觸皮膚時，上面的微型針頭在幾秒內(nèi)就會把疫苗注入體內(nèi)。

It can last for up to three months at room temperature, unlike other jabs that need to be stored in the freezer or fridge.

貼片疫苗與其他需存放在低溫環(huán)境中的新冠疫苗不同，可以在室溫下保存長達(dá)3個月。

Emergex has received the green light from the Swiss drugs regulator to conduct initial human trials in Lausanne starting on Jan 3.

Emergex公司已獲得瑞士藥品監(jiān)管機(jī)構(gòu)的批準(zhǔn)，并將于明年1月3日開始在洛桑開展初期臨床試驗(yàn)。

Interim results from the trial are expected in June.

試驗(yàn)的中期結(jié)果預(yù)計(jì)將于6月公布。